Navigation Links
NSF awards $1.5M for study of in-home health care via wireless networks
Date:4/24/2008

HOUSTON, April 24, 2008 -- Rice University, The Methodist Hospital Research Institute and Technology For All (TFA) have received a $1.5 million federal grant for research in east Houston that will examine ways to provide novel, low-cost, personalized health monitoring to people with chronic diseases living in working-class communities.

The researchers plan to examine how patients with chronic diseases use inexpensive handheld wireless monitoring devices called Blue Boxes, to participate actively in their own medical treatment. The National Science Foundation (NSF) grant will pay for the development and testing of the Blue Boxes and the wireless broadband network that will connect the devices to a central source for analysis.

The project brings together wireless researchers from Rice, chronic health care researchers and decision scientists at The Methodist Hospital Research Institutes and University of Houston's Abramson Center for the Future of Health, and experts from TFA, a Houston non-profit that operates the TFA-Wireless network in east Houston's Pecan Park.

The Abramson Center is a collaboration between The Methodist Hospital Research Institute and the University of Houston's College of Technology.

"Our development of a low-cost, easy to use, hand-held health monitoring device called the Blue Box makes personalized health care much more accessible to all patients with chronic illness, said Dr. Clifford Dacso, the John S. Dunn Sr. Research Chair in internal medicine at The Methodist Hospital and executive director of the Abramson Center, a co-principal investigator on the project. Combining the Blue Box technology with an existing wireless network is designed to allow people with chronic illnesses to fine-tune their health, thus avoiding preventable deterioration that may result in emergency care. Its much easier on the patient and provides them with higher quality, very personal care."

The NSF funding will ena
'/>"/>

Contact: Jade Boyd
jadeboyd@rice.edu
713-348-6778
Rice University
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Cadient Group Receives Multiple Awards at 2008 DTC National Advertising Awards
2. GHXcellence Awards Honor Healthcare Providers and Suppliers for Achievements in Supply Chain Performance
3. United American Healthcare Corporation Provides Update on TennCare RFP Awards
4. Herley Awarded $1 Million in Awards for Integrated Microwave Assemblies for U.S. Military Aircraft
5. Omnicoms Diversified Agency Services Healthcare Agencies Top Med Ad News Manny Awards
6. Life Sciences Fund grants awards to launch health research
7. Life Sciences Discovery Fund Awards $2.2 Million to Support New Solid-Tumor Research Program
8. Mental Health Prescription Program Named Winner in URACs Best Practices in Consumer Empowerment and Protection Awards
9. The BBVA Foundation awards its 2007 Biomedicine Chairs
10. The Pancreatic Cancer Action Network Announces Its 2008 Research Grant Awards Totaling Over $1 Million in New Research Funding
11. American Cancer Society awards research grants to 133 investigators at 84 institutions nationwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...RNewswire/ -- The general membership of the Medica...new individuals at their Annual,Awards Dinner to ...ew York. A,Lifetime Achievement Award will also b...cal Advertising Hall of Fame are: , Ronald Pant...ount position,at Sudler & Hennessey. In 1980 ...
(Date:11/21/2008)...r drugs do not cause genetic damage that can lead ...y News) -- Two popular medications for treating at...ot cause genetic damage linked to an increased ris...e study, done by researchers at Duke University Me..., counters a previous one that reported biomarkers...
(Date:11/21/2008)...ewswire/ -- In a statewide survey, 33 physicians c... Surgery at Presbyterian Hospital of Dallas were h...ng of " Super Doctors ." , , Each year, the...ssional Media, Inc. to survey more than 38,000 med...k, "If you needed medical care, which doctor would...
(Date:11/21/2008)...1 Symmetry Medical Inc. ...products to the global orthopedic device industry ...ian S. Moore, President and Chief Executive Office...ef Financial Officer, are scheduled to present at ...ce at The New York Palace Hotel on Wednesday, Dece...
Breaking Medicine News(10 mins):Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 2Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 3Health News:ADHD Medications Don't Pose Cancer Risk 2Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2
...rder from genetic sources can also be responsible ...cular development. Researchers at Children’s Hosp...cs // of rare eye-movement disorders, have found ...ns go far beyond the eye, raising intriguing quest...
... acids better known for their close association to...t cancer cells. Dietary intake of omega 3 fatty ac...entaenoic acid (EPA) // may curb the growth of br...to a study published in the International Journal ...
...ch companies like Pfizer are increasingly interest...se products are in the early phase 2 clinical tria...der acquisition then they used to be,” notes Roger... information specialist for Windhover information....
...esearcher Olga Raz is all set to launch her diet p...ight, in US and other parts of the world through h... Weight Loss Plan.// The diet features bread, and...r women and 16 slices a day for men – plus lots of...
Other Medicine News:Health News:Genetic Eye Disorder Can Have Other Implications 2
(Date:11/21/2008)... , - Not for UK J...icinal Products for Human Use (CHMP) today,announ...f Enbrel(R),(etanercept) as a treatment for child...vere plaque psoriasis. If approved by the European...tion, Enbrel will become the,first biologic treat...
(Date:11/20/2008)...PHIA, Nov. 20 GlaxoSmithK...d States Food and Drug Administration (FDA) grante...g) for the treatment of thrombocytopenia in patien...ic purpura (ITP) who have had an insufficient resp...ctomy. The approval is a significant milestone for...
(Date:11/20/2008)...swire-FirstCall/ -- Duska Therapeutics,Inc., (OT...as submitted its,pivotal Phase 3 ATPace clinical ...l Assessment (SPA) procedure with the U.S. Food an...securing an agreement with the FDA, Duska intends ...placebo-controlled and randomized Phase 3,clinica...
(Date:11/19/2008)...re/ -- Posit Science Corporation,researcher, Dan ...oscience,Annual Conference in Washington, DC this...fit Baby Boomers. The computerized brain plastici... exercises that target auditory and,language syst...zed,improvements in cognition by improving speed ...
Breaking Medicine Technology:CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 2CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 3CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 4CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults 2Long Term Data from a Landmark Phase III Trial Show Survival Benefit at Three and Four Years in Patients with Glioblastoma multiforme 698 1Long Term Data from a Landmark Phase III Trial Show Survival Benefit at Three and Four Years in Patients with Glioblastoma multiforme 698 2Long Term Data from a Landmark Phase III Trial Show Survival Benefit at Three and Four Years in Patients with Glioblastoma multiforme 698 3Long Term Data from a Landmark Phase III Trial Show Survival Benefit at Three and Four Years in Patients with Glioblastoma multiforme 698 4Long Term Data from a Landmark Phase III Trial Show Survival Benefit at Three and Four Years in Patients with Glioblastoma multiforme 698 5CEL SCI to Present at Rodman 26 Renshaw 9th Annual Healthcare Conference 695 1CEL SCI to Present at Rodman 26 Renshaw 9th Annual Healthcare Conference 695 2AIDS Stopped in Haiti Before U S 4956 1AIDS Stopped in Haiti Before U S 4956 2AIDS Stopped in Haiti Before U S 4956 3Neurobiological Technologies Announces Pricing of Its 2460 Million Common Stock Offering 1579 1Neurobiological Technologies Announces Pricing of Its 2460 Million Common Stock Offering 1579 2
...th Humira Estimated to Increase the,Maximal Steady...0%,-, SAN DIEGO, July 09, 2007 /PRNewswire-FirstCa...utical company developing and,commercializing reco...results of the Enhanze(TM) Technology clinical tri...bility of a,representative commercially-available ...
...S WIRE)--Jul 11, 2007 - BioSante,Pharmaceuticals, ...lts demonstrating that its calcium phosphate (CaP)... may serve as an,effective vaccine adjuvant for th...N1 avian flu, widely known as bird flu., The new r...on,inhibition assay (HAI), which showed the clear ...
Other Medicine Technology:Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 2Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 3Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 4Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 5BioSante Pharmaceuticals Announces New Findings for Potential Bird,Flu Vaccine 2BioSante Pharmaceuticals Announces New Findings for Potential Bird,Flu Vaccine 3BioSante Pharmaceuticals Announces New Findings for Potential Bird,Flu Vaccine 4
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
Medicine Products: